社区
首页
集团介绍
社区
资讯
行情
学堂
TigerAI
登录
注册
北_4560
IP属地:北京
+关注
帖子 · 16
帖子 · 16
关注 · 0
关注 · 0
粉丝 · 0
粉丝 · 0
北_4560
北_4560
·
2021-08-19
还有天理没,天天爹
恒瑞医药可以一点一点建仓。
恒瑞医药可以一点一点建仓。 JIANGSU HENGRUI PHARMACEUTICALS CO.,LTD. SSE:600276 hujianghua 1、恒瑞医药月线看布林带下轨有支撑。 2、斐波那契回撤到0.618黄金分割线,54.67的位置,同布林带产生支撑共振。 3、这个位置我们可以一点一点建仓,不超过总仓位的20%。 4、耐心等待打破红色下跌趋势线后,右侧大仓位买入是最稳妥的。
恒瑞医药可以一点一点建仓。
看
3,375
回复
评论
点赞
点赞
编组 21备份 2
分享
举报
北_4560
北_4560
·
2021-07-06
跌倒100左右就正常了
非常抱歉,此主贴已删除
看
1,979
回复
评论
点赞
1
编组 21备份 2
分享
举报
北_4560
北_4560
·
2021-06-24
估值太高,应该会跌破发行价
阳光诺和科创板上市:市值95亿 实控人利虔大专肄业
阳光诺和此次发行2000万股,发行价为26.89元,募资总额5.38亿元。阳光诺和首日开盘价为131元,较发行价上涨387%;收盘价为120.09元,较发行价上涨346.6%;以收盘价计算,阳光诺和市值为96亿元。截至今日,阳光诺和股价下跌0.87%,市值为95.12亿元。实控人利虔大专肄业IPO前,阳光诺和实际控制人利虔持股比例为36.78%,刘宇晶直接持有公司4,280,860股股份,持股7.13%,在公司担任董事、总经理职务。
阳光诺和科创板上市:市值95亿 实控人利虔大专肄业
看
3,003
回复
评论
点赞
1
编组 21备份 2
分享
举报
北_4560
北_4560
·
2021-06-21
后续全让你吐出来
非常抱歉,此主贴已删除
看
2,643
回复
评论
点赞
1
编组 21备份 2
分享
举报
北_4560
北_4560
·
2021-05-21
不是不跌,是不到时候[笑哭]
非常抱歉,此主贴已删除
看
2,320
回复
评论
点赞
1
编组 21备份 2
分享
举报
北_4560
北_4560
·
2021-05-17
都有问题,绝对的,被人家抓住把柄了。
非常抱歉,此主贴已删除
看
2,645
回复
评论
点赞
4
编组 21备份 2
分享
举报
北_4560
北_4560
·
2021-05-12
继续
非常抱歉,此主贴已删除
看
1,824
回复
评论
点赞
4
编组 21备份 2
分享
举报
北_4560
北_4560
·
2021-02-01
查吧[开心]
非常抱歉,此主贴已删除
看
2,738
回复
评论
点赞
点赞
编组 21备份 2
分享
举报
北_4560
北_4560
·
2021-01-29
支持,实事求是!再有钱能大过法?
非常抱歉,此主贴已删除
看
2,700
回复
评论
点赞
1
编组 21备份 2
分享
举报
北_4560
北_4560
·
2021-01-12
通过也拉不起股票,进入集采可以😊
悦康药业(688658.SH):降血糖药盐酸二甲双胍片通过仿制药一致性评价
智通财经APP讯,悦康药业(688658.SH)发布公告,近日,该公司收到国家药品监督管理局核准签发的关于盐酸二甲双胍片(0.25g)的《药品补充申请批准通知书》,该药品通过仿制药质量和疗效一致性评价。据悉,盐酸二甲双胍片为双胍类口服降血糖药物,适应人群广,成人和10岁及以上儿童和青少年均可适用。
悦康药业(688658.SH):降血糖药盐酸二甲双胍片通过仿制药一致性评价
看
2,953
回复
评论
点赞
1
编组 21备份 2
分享
举报
加载更多
暂无关注
热议股票
{"i18n":{"language":"zh_CN"},"isCurrentUser":false,"userPageInfo":{"id":"3546384736338140","uuid":"3546384736338140","gmtCreate":1583290714534,"gmtModify":1624520953321,"name":"北_4560","pinyin":"b4560bei4560","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.tigerbbs.com/711d3d2faa9de841ae9246d53fa589ec","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":0,"headSize":6,"tweetSize":16,"questionSize":0,"limitLevel":999,"accountStatus":2,"level":{"id":2,"name":"无畏虎","nameTw":"無畏虎","represent":"初生牛犊","factor":"发布3条非转发主帖,1条获得他人回复或点赞","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":6,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":"success","userBadges":[{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-4","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"明星虎友","description":"加入老虎社区2000天","bigImgUrl":"https://static.tigerbbs.com/dddf24b906c7011de2617d4fb3f76987","smallImgUrl":"https://static.tigerbbs.com/53d58ad32c97254c6f74db8b97e6ec49","grayImgUrl":"https://static.tigerbbs.com/6304700d92ad91c7a33e2e92ec32ecc1","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2025.08.26","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001}],"userBadgeCount":1,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":1,"crmLevelSwitch":0,"location":"北京","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"page":1,"watchlist":null,"tweetList":[{"id":831745039,"gmtCreate":1629353770021,"gmtModify":1629353770021,"author":{"id":"3546384736338140","authorId":"3546384736338140","name":"北_4560","avatar":"https://static.tigerbbs.com/711d3d2faa9de841ae9246d53fa589ec","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3546384736338140","authorIdStr":"3546384736338140"},"themes":[],"htmlText":"还有天理没,天天爹","listText":"还有天理没,天天爹","text":"还有天理没,天天爹","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/831745039","repostId":"2160271696","repostType":2,"repost":{"id":"2160271696","kind":"highlight","weMediaInfo":{"introduction":"Live quotes, stock charts and expert trading ideas. TradingView is a social network for traders and investors on Stock, Futures and Forex markets!","home_visible":1,"media_name":"TradingView","id":"1083892989","head_image":"https://static.tigerbbs.com/d298bab1e4184c87f17c1e0be9b9d329"},"pubTimestamp":1629125676,"share":"https://www.laohu8.com/m/news/2160271696?lang=&edition=full","pubTime":"2021-08-16 22:54","market":"hk","language":"zh","title":"恒瑞医药可以一点一点建仓。","url":"https://stock-news.laohu8.com/highlight/detail?id=2160271696","media":"TradingView","summary":"恒瑞医药可以一点一点建仓。\n\n\nJIANGSU HENGRUI PHARMACEUTICALS CO.,LTD. SSE:600276\n\n\nhujianghua\n\n\n1、恒瑞医药月线看布林带下轨有支撑。 \n2、斐波那契回撤到0.618黄金分割线,54.67的位置,同布林带产生支撑共振。 \n3、这个位置我们可以一点一点建仓,不超过总仓位的20%。 \n4、耐心等待打破红色下跌趋势线后,右侧大仓位买入是最稳妥的。","content":"<html><body><div>\n<img height=\"32\" src=\"https://s3.tradingview.com/userpics/1988963-NFBn_mid.png\" width=\"32\"/>\n</div>\n<div>\n<h1><a href=\"https://laohu8.com/S/600276\">恒瑞医药</a>可以一点一点建仓。</h1>\n</div>\n<div>\nJIANGSU HENGRUI PHARMACEUTICALS CO.,LTD. <span>SSE:600276</span>\n</div>\n<div>\nhujianghua\n</div>\n<img src=\"https://s3.tradingview.com/f/FEkQShry_mid.png\"/>\n<p>1、恒瑞医药月线看布林带下轨有支撑。 \n2、斐波那契回撤到0.618黄金分割线,54.67的位置,同布林带产生支撑共振。 \n3、这个位置我们可以一点一点建仓,不超过总仓位的20%。 \n4、耐心等待打破红色下跌<a href=\"https://laohu8.com/S/42T.SI\">趋势线</a>后,右侧大仓位买入是最稳妥的。</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>恒瑞医药可以一点一点建仓。</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n恒瑞医药可以一点一点建仓。\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1083892989\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d298bab1e4184c87f17c1e0be9b9d329);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">TradingView </p>\n<p class=\"h-time\">2021-08-16 22:54</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><div>\n<img height=\"32\" src=\"https://s3.tradingview.com/userpics/1988963-NFBn_mid.png\" width=\"32\"/>\n</div>\n<div>\n<h1><a href=\"https://laohu8.com/S/600276\">恒瑞医药</a>可以一点一点建仓。</h1>\n</div>\n<div>\nJIANGSU HENGRUI PHARMACEUTICALS CO.,LTD. <span>SSE:600276</span>\n</div>\n<div>\nhujianghua\n</div>\n<img src=\"https://s3.tradingview.com/f/FEkQShry_mid.png\"/>\n<p>1、恒瑞医药月线看布林带下轨有支撑。 \n2、斐波那契回撤到0.618黄金分割线,54.67的位置,同布林带产生支撑共振。 \n3、这个位置我们可以一点一点建仓,不超过总仓位的20%。 \n4、耐心等待打破红色下跌<a href=\"https://laohu8.com/S/42T.SI\">趋势线</a>后,右侧大仓位买入是最稳妥的。</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/753c9aba3202037bc97463c545d5d015","relate_stocks":{"600276":"恒瑞医药"},"source_url":"https://cn.tradingview.com/chart/600276/FEkQShry/","is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2160271696","content_text":"恒瑞医药可以一点一点建仓。\n\n\nJIANGSU HENGRUI PHARMACEUTICALS CO.,LTD. SSE:600276\n\n\nhujianghua\n\n\n1、恒瑞医药月线看布林带下轨有支撑。 \n2、斐波那契回撤到0.618黄金分割线,54.67的位置,同布林带产生支撑共振。 \n3、这个位置我们可以一点一点建仓,不超过总仓位的20%。 \n4、耐心等待打破红色下跌趋势线后,右侧大仓位买入是最稳妥的。","news_type":1,"symbols_score_info":{"600276":1}},"isVote":1,"tweetType":1,"viewCount":3375,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":154480493,"gmtCreate":1625538743912,"gmtModify":1625538743912,"author":{"id":"3546384736338140","authorId":"3546384736338140","name":"北_4560","avatar":"https://static.tigerbbs.com/711d3d2faa9de841ae9246d53fa589ec","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3546384736338140","authorIdStr":"3546384736338140"},"themes":[],"htmlText":"跌倒100左右就正常了","listText":"跌倒100左右就正常了","text":"跌倒100左右就正常了","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/154480493","repostId":"2148752488","repostType":2,"isVote":1,"tweetType":1,"viewCount":1979,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":128294443,"gmtCreate":1624517347282,"gmtModify":1624517347282,"author":{"id":"3546384736338140","authorId":"3546384736338140","name":"北_4560","avatar":"https://static.tigerbbs.com/711d3d2faa9de841ae9246d53fa589ec","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3546384736338140","authorIdStr":"3546384736338140"},"themes":[],"htmlText":"估值太高,应该会跌破发行价","listText":"估值太高,应该会跌破发行价","text":"估值太高,应该会跌破发行价","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/128294443","repostId":"2145110068","repostType":2,"repost":{"id":"2145110068","kind":"highlight","weMediaInfo":{"introduction":"欢迎收听雷帝触网,雷帝触网是中国最多产的互联网科技自媒体,内容中立,快、准、狠,其由资深媒体人雷建平创办,雷建平是今日头条签约作家,也入驻了一点资讯、搜狐、网易等平台。","home_visible":1,"media_name":"雷递","id":"52","head_image":"https://static.tigerbbs.com/f45a6cbcc8ec48a7a2f52177324d0c16"},"pubTimestamp":1624371780,"share":"https://www.laohu8.com/m/news/2145110068?lang=&edition=full","pubTime":"2021-06-22 22:23","market":"us","language":"zh","title":"阳光诺和科创板上市:市值95亿 实控人利虔大专肄业","url":"https://stock-news.laohu8.com/highlight/detail?id=2145110068","media":"雷递","summary":"阳光诺和此次发行2000万股,发行价为26.89元,募资总额5.38亿元。阳光诺和首日开盘价为131元,较发行价上涨387%;收盘价为120.09元,较发行价上涨346.6%;以收盘价计算,阳光诺和市值为96亿元。截至今日,阳光诺和股价下跌0.87%,市值为95.12亿元。实控人利虔大专肄业IPO前,阳光诺和实际控制人利虔持股比例为36.78%,刘宇晶直接持有公司4,280,860股股份,持股7.13%,在公司担任董事、总经理职务。","content":"<html><body><div>\n<p><img arial=\"\" border-box=\"\" break-word=\"\" gb=\"\" helvetica=\"\" neue=\"\" normal=\"\" rgb=\"\" sans=\"\" sans-serif=\"\" sc=\"\" src=\"https://static.tigerbbs.com/3c3de296d4c24bd595aa0ae6fe9d7fb0\" ui=\"\" visible=\"\" yahei=\"\"/></p><p><strong>雷递网 雷建平 6月22日报道</strong></p><p>北京<a href=\"https://laohu8.com/S/688621\">阳光诺和</a>药物研究股份有限公司(证券代码:688621,简称:“阳光诺和”)昨日在科创板上市,发行价为26.89元。</p><p>阳光诺和此次发行2000万股,发行价为26.89元,募资总额5.38亿元。</p><p><img arial=\"\" border-box=\"\" break-word=\"\" gb=\"\" helvetica=\"\" neue=\"\" normal=\"\" rgb=\"\" sans=\"\" sans-serif=\"\" sc=\"\" src=\"https://static.tigerbbs.com/0bf04fd2b6454f7e8d719d25fc3fa031\" ui=\"\" visible=\"\" yahei=\"\"/></p><p>阳光诺和首日开盘价为131元,较发行价上涨387%;收盘价为120.09元,较发行价上涨346.6%;以收盘价计算,阳光诺和市值为96亿元。</p><p>截至今日,阳光诺和股价下跌0.87%,市值为95.12亿元。</p><p><strong>年营收3.47亿</strong></p><p><img arial=\"\" border-box=\"\" break-word=\"\" gb=\"\" helvetica=\"\" neue=\"\" normal=\"\" rgb=\"\" sans=\"\" sans-serif=\"\" sc=\"\" src=\"https://static.tigerbbs.com/7b88bbeca2764a65808e957abfb242b4\" ui=\"\" visible=\"\" yahei=\"\"/></p><p>阳光诺和成立于2009年,是国内较早对外提供药物研发服务的CRO公司(ContractResearchOrganization,合同研究组织)之一。公司位于北京市昌平区。</p><p><img arial=\"\" border-box=\"\" break-word=\"\" center=\"\" gb=\"\" helvetica=\"\" neue=\"\" normal=\"\" rgb=\"\" sans=\"\" sans-serif=\"\" sc=\"\" src=\"https://static.tigerbbs.com/21bf44e9a9e54929adcd7c5e926f0bac\" ui=\"\" visible=\"\" yahei=\"\"/></p><p>公司作为医药制造企业可借用的一种外部资源,在接受客户委托后,可以在短时间内迅速组织起一支具有高度专业化和丰富经验的研究队伍,从而帮助医药制造企业加快药物研发进展,降低药物研发费用,并实现高质量的研究。</p><p><img arial=\"\" border-box=\"\" break-word=\"\" center=\"\" gb=\"\" helvetica=\"\" neue=\"\" normal=\"\" rgb=\"\" sans=\"\" sans-serif=\"\" sc=\"\" src=\"https://static.tigerbbs.com/3f141d8f24f94bb88ab1d02cc74b3232\" ui=\"\" visible=\"\" yahei=\"\"/></p><p>阳光诺和2018年、2019年、2020年营收分别为1.35亿元、2.34亿元、3.47亿元;净利润分别为2016万元、4793.3万元、7416.26万元。</p><p><img src=\"https://static.tigerbbs.com/acd6b701869d494aba7187d41cbb8f9a\"/></p><p>报告期内各期,公司仿制药一致性评价业务的收入分别为3205万、6281万和6271万,占当期主营业务收入的比例分别为23.78%、26.93%和18.08%。</p><p>阳光诺和2021年一季度营收为9577.08万元,同比增长29.82%;实现归属于母公司股东的净利润2053.48万元,同比增长19.01%;实现扣除非经常性损益后归属于母公司股东的净利润2011.81万元,同比增长14.78%。</p><p>阳光诺和2021年1-6月营业收入预计为2亿元到2.4亿元,较上年同期变动幅度为28.45%-54.14%;净利润预计为4500万元-5400万元,较上年同期变动幅度为12.03%-34.44%;归属于母公司股东的净利润预计为4350万元到5250万元,较上年同期变动幅度为6.49%-28.52%;</p><p>阳光诺和2021年1-6月扣除非经常性损益后归属于母公司股东的净利润预计为4300万元到5300万元,较去年同期变动幅度为4.99%-29.41%。</p><p><strong>实控人利虔大专肄业</strong></p><p><img arial=\"\" border-box=\"\" break-word=\"\" gb=\"\" helvetica=\"\" neue=\"\" normal=\"\" rgb=\"\" sans=\"\" sans-serif=\"\" sc=\"\" src=\"https://static.tigerbbs.com/3c1fee5a6c1c4fe7b6963b9be8e5feaa\" ui=\"\" visible=\"\" yahei=\"\"/></p><p>IPO前,阳光诺和实际控制人利虔持股比例为36.78%,刘宇晶直接持有公司4,280,860股股份,持股7.13%,在公司担任董事、总经理职务。</p><p>利虔,男,1981年11月出生,北京医科大学(现北京大学医学部)大专肄业。2002年7月至2005年6月,历任北京德众万全药物技术开发有限公司合成部实验员、项目经理、项目立项组组长;2005年6月至2014年6月,任北京聚德阳光医药科技有限公司执行董事、总经理;</p><p>利虔2009年3月投资创建阳光诺和有限,2009年3月至2011年9月,任阳光诺和有限执行董事、总经理;2011年9月至2016年3月,任阳光诺和有限董事、总经理;2016年3月至2016年7月,任阳光诺和有限执行董事、总经理;2016年2月至今,任朗研生命执行董事;2016年3月至今,任百奥药业董事长;利虔2016年12月至今,任永安制药董事长;</p><p>利虔现兼任朗研生命总经理,百奥药业总经理,北京屹东博杰科技有限责任公司监事;2020年3月至今,任阳光诺和董事长。</p><p><img src=\"https://static.tigerbbs.com/86737a66cc4645baa714b69df23e8df4\"/></p><p>此外,杭州方汭持股为4.75%,邵妍、托新权分别持股为4%,佛山景祥持股为3.38%,凯泰民德持股为3.07%;</p><p>信德一期持股为2.68%,海达明德持股为2.61%,睿盈投资持股为2.33%,广州正达持股为2.23%;泰达盛林持股为2.2%;</p><p>武汉火炬、武汉开投分别持股为1.82%,广发乾和持股为1.46%,民生投资持股为1.25%。</p><p><img src=\"https://static.tigerbbs.com/fe5c82fec6e540549eb13e96b3ca5bb8\"/></p><p>IPO后,实际控制人利虔持股比例将进一步稀释为27.59%,刘宇晶持股为5.35%,杭州方汭持股为3.57%,邵妍、托新权分别持股为3%。</p><p arial=\"\" break-word=\"\" gb=\"\" helvetica=\"\" neue=\"\" rgb=\"\" sans=\"\" sans-serif=\"\" sc=\"\" transparent=\"\" ui=\"\" yahei=\"\"><span>———————————————</span></p><p arial=\"\" break-word=\"\" gb=\"\" helvetica=\"\" neue=\"\" rgb=\"\" sans=\"\" sans-serif=\"\" sc=\"\" transparent=\"\" ui=\"\" yahei=\"\"><span>雷递由资深媒体人雷建平创办,为头条签约作者,若转载请写明来源。</span></p><p arial=\"\" break-word=\"\" gb=\"\" helvetica=\"\" neue=\"\" rgb=\"\" sans=\"\" sans-serif=\"\" sc=\"\" transparent=\"\" ui=\"\" yahei=\"\"><span><img arial=\"\" border-box=\"\" break-word=\"\" center=\"\" gb=\"\" helvetica=\"\" neue=\"\" sans=\"\" sans-serif=\"\" sc=\"\" src=\"https://static.tigerbbs.com/44ede28b224d4e13b49d62221701b7b4\" ui=\"\" visible=\"\" yahei=\"\"/></span></p><p arial=\"\" border-box=\"\" break-word=\"\" gb=\"\" helvetica=\"\" neue=\"\" rgb=\"\" sans=\"\" sans-serif=\"\" sc=\"\" ui=\"\" yahei=\"\"><img src=\"https://static.tigerbbs.com/375bcd2bd4434f53bab3d31f98bfd884\"/></p>\n</div></body></html>","source":"weixin_highlight","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>阳光诺和科创板上市:市值95亿 实控人利虔大专肄业</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n阳光诺和科创板上市:市值95亿 实控人利虔大专肄业\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/52\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/f45a6cbcc8ec48a7a2f52177324d0c16);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">雷递 </p>\n<p class=\"h-time\">2021-06-22 22:23</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><div>\n<p><img arial=\"\" border-box=\"\" break-word=\"\" gb=\"\" helvetica=\"\" neue=\"\" normal=\"\" rgb=\"\" sans=\"\" sans-serif=\"\" sc=\"\" src=\"https://static.tigerbbs.com/3c3de296d4c24bd595aa0ae6fe9d7fb0\" ui=\"\" visible=\"\" yahei=\"\"/></p><p><strong>雷递网 雷建平 6月22日报道</strong></p><p>北京<a href=\"https://laohu8.com/S/688621\">阳光诺和</a>药物研究股份有限公司(证券代码:688621,简称:“阳光诺和”)昨日在科创板上市,发行价为26.89元。</p><p>阳光诺和此次发行2000万股,发行价为26.89元,募资总额5.38亿元。</p><p><img arial=\"\" border-box=\"\" break-word=\"\" gb=\"\" helvetica=\"\" neue=\"\" normal=\"\" rgb=\"\" sans=\"\" sans-serif=\"\" sc=\"\" src=\"https://static.tigerbbs.com/0bf04fd2b6454f7e8d719d25fc3fa031\" ui=\"\" visible=\"\" yahei=\"\"/></p><p>阳光诺和首日开盘价为131元,较发行价上涨387%;收盘价为120.09元,较发行价上涨346.6%;以收盘价计算,阳光诺和市值为96亿元。</p><p>截至今日,阳光诺和股价下跌0.87%,市值为95.12亿元。</p><p><strong>年营收3.47亿</strong></p><p><img arial=\"\" border-box=\"\" break-word=\"\" gb=\"\" helvetica=\"\" neue=\"\" normal=\"\" rgb=\"\" sans=\"\" sans-serif=\"\" sc=\"\" src=\"https://static.tigerbbs.com/7b88bbeca2764a65808e957abfb242b4\" ui=\"\" visible=\"\" yahei=\"\"/></p><p>阳光诺和成立于2009年,是国内较早对外提供药物研发服务的CRO公司(ContractResearchOrganization,合同研究组织)之一。公司位于北京市昌平区。</p><p><img arial=\"\" border-box=\"\" break-word=\"\" center=\"\" gb=\"\" helvetica=\"\" neue=\"\" normal=\"\" rgb=\"\" sans=\"\" sans-serif=\"\" sc=\"\" src=\"https://static.tigerbbs.com/21bf44e9a9e54929adcd7c5e926f0bac\" ui=\"\" visible=\"\" yahei=\"\"/></p><p>公司作为医药制造企业可借用的一种外部资源,在接受客户委托后,可以在短时间内迅速组织起一支具有高度专业化和丰富经验的研究队伍,从而帮助医药制造企业加快药物研发进展,降低药物研发费用,并实现高质量的研究。</p><p><img arial=\"\" border-box=\"\" break-word=\"\" center=\"\" gb=\"\" helvetica=\"\" neue=\"\" normal=\"\" rgb=\"\" sans=\"\" sans-serif=\"\" sc=\"\" src=\"https://static.tigerbbs.com/3f141d8f24f94bb88ab1d02cc74b3232\" ui=\"\" visible=\"\" yahei=\"\"/></p><p>阳光诺和2018年、2019年、2020年营收分别为1.35亿元、2.34亿元、3.47亿元;净利润分别为2016万元、4793.3万元、7416.26万元。</p><p><img src=\"https://static.tigerbbs.com/acd6b701869d494aba7187d41cbb8f9a\"/></p><p>报告期内各期,公司仿制药一致性评价业务的收入分别为3205万、6281万和6271万,占当期主营业务收入的比例分别为23.78%、26.93%和18.08%。</p><p>阳光诺和2021年一季度营收为9577.08万元,同比增长29.82%;实现归属于母公司股东的净利润2053.48万元,同比增长19.01%;实现扣除非经常性损益后归属于母公司股东的净利润2011.81万元,同比增长14.78%。</p><p>阳光诺和2021年1-6月营业收入预计为2亿元到2.4亿元,较上年同期变动幅度为28.45%-54.14%;净利润预计为4500万元-5400万元,较上年同期变动幅度为12.03%-34.44%;归属于母公司股东的净利润预计为4350万元到5250万元,较上年同期变动幅度为6.49%-28.52%;</p><p>阳光诺和2021年1-6月扣除非经常性损益后归属于母公司股东的净利润预计为4300万元到5300万元,较去年同期变动幅度为4.99%-29.41%。</p><p><strong>实控人利虔大专肄业</strong></p><p><img arial=\"\" border-box=\"\" break-word=\"\" gb=\"\" helvetica=\"\" neue=\"\" normal=\"\" rgb=\"\" sans=\"\" sans-serif=\"\" sc=\"\" src=\"https://static.tigerbbs.com/3c1fee5a6c1c4fe7b6963b9be8e5feaa\" ui=\"\" visible=\"\" yahei=\"\"/></p><p>IPO前,阳光诺和实际控制人利虔持股比例为36.78%,刘宇晶直接持有公司4,280,860股股份,持股7.13%,在公司担任董事、总经理职务。</p><p>利虔,男,1981年11月出生,北京医科大学(现北京大学医学部)大专肄业。2002年7月至2005年6月,历任北京德众万全药物技术开发有限公司合成部实验员、项目经理、项目立项组组长;2005年6月至2014年6月,任北京聚德阳光医药科技有限公司执行董事、总经理;</p><p>利虔2009年3月投资创建阳光诺和有限,2009年3月至2011年9月,任阳光诺和有限执行董事、总经理;2011年9月至2016年3月,任阳光诺和有限董事、总经理;2016年3月至2016年7月,任阳光诺和有限执行董事、总经理;2016年2月至今,任朗研生命执行董事;2016年3月至今,任百奥药业董事长;利虔2016年12月至今,任永安制药董事长;</p><p>利虔现兼任朗研生命总经理,百奥药业总经理,北京屹东博杰科技有限责任公司监事;2020年3月至今,任阳光诺和董事长。</p><p><img src=\"https://static.tigerbbs.com/86737a66cc4645baa714b69df23e8df4\"/></p><p>此外,杭州方汭持股为4.75%,邵妍、托新权分别持股为4%,佛山景祥持股为3.38%,凯泰民德持股为3.07%;</p><p>信德一期持股为2.68%,海达明德持股为2.61%,睿盈投资持股为2.33%,广州正达持股为2.23%;泰达盛林持股为2.2%;</p><p>武汉火炬、武汉开投分别持股为1.82%,广发乾和持股为1.46%,民生投资持股为1.25%。</p><p><img src=\"https://static.tigerbbs.com/fe5c82fec6e540549eb13e96b3ca5bb8\"/></p><p>IPO后,实际控制人利虔持股比例将进一步稀释为27.59%,刘宇晶持股为5.35%,杭州方汭持股为3.57%,邵妍、托新权分别持股为3%。</p><p arial=\"\" break-word=\"\" gb=\"\" helvetica=\"\" neue=\"\" rgb=\"\" sans=\"\" sans-serif=\"\" sc=\"\" transparent=\"\" ui=\"\" yahei=\"\"><span>———————————————</span></p><p arial=\"\" break-word=\"\" gb=\"\" helvetica=\"\" neue=\"\" rgb=\"\" sans=\"\" sans-serif=\"\" sc=\"\" transparent=\"\" ui=\"\" yahei=\"\"><span>雷递由资深媒体人雷建平创办,为头条签约作者,若转载请写明来源。</span></p><p arial=\"\" break-word=\"\" gb=\"\" helvetica=\"\" neue=\"\" rgb=\"\" sans=\"\" sans-serif=\"\" sc=\"\" transparent=\"\" ui=\"\" yahei=\"\"><span><img arial=\"\" border-box=\"\" break-word=\"\" center=\"\" gb=\"\" helvetica=\"\" neue=\"\" sans=\"\" sans-serif=\"\" sc=\"\" src=\"https://static.tigerbbs.com/44ede28b224d4e13b49d62221701b7b4\" ui=\"\" visible=\"\" yahei=\"\"/></span></p><p arial=\"\" border-box=\"\" break-word=\"\" gb=\"\" helvetica=\"\" neue=\"\" rgb=\"\" sans=\"\" sans-serif=\"\" sc=\"\" ui=\"\" yahei=\"\"><img src=\"https://static.tigerbbs.com/375bcd2bd4434f53bab3d31f98bfd884\"/></p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/e0ab8365ea89ee143187cbf51d23ba8f","relate_stocks":{"688621":"阳光诺和"},"source_url":"http://mp.weixin.qq.com/s?__biz=MjM5MzQ5NjIyMQ==&mid=2661514982&idx=4&sn=7de48bdeedb8e3a4d9478abfecea9b49&chksm=bdc1f3148ab67a0260376e736148ef78fabe7c82f679e698f1bc3702ba73b2b079444fccbbd0&scene=0#rd","is_english":false,"share_image_url":"https://static.laohu8.com/ecd74548980bc5b366aa8f4b37ed0bd5","article_id":"2145110068","content_text":"雷递网 雷建平 6月22日报道北京阳光诺和药物研究股份有限公司(证券代码:688621,简称:“阳光诺和”)昨日在科创板上市,发行价为26.89元。阳光诺和此次发行2000万股,发行价为26.89元,募资总额5.38亿元。阳光诺和首日开盘价为131元,较发行价上涨387%;收盘价为120.09元,较发行价上涨346.6%;以收盘价计算,阳光诺和市值为96亿元。截至今日,阳光诺和股价下跌0.87%,市值为95.12亿元。年营收3.47亿阳光诺和成立于2009年,是国内较早对外提供药物研发服务的CRO公司(ContractResearchOrganization,合同研究组织)之一。公司位于北京市昌平区。公司作为医药制造企业可借用的一种外部资源,在接受客户委托后,可以在短时间内迅速组织起一支具有高度专业化和丰富经验的研究队伍,从而帮助医药制造企业加快药物研发进展,降低药物研发费用,并实现高质量的研究。阳光诺和2018年、2019年、2020年营收分别为1.35亿元、2.34亿元、3.47亿元;净利润分别为2016万元、4793.3万元、7416.26万元。报告期内各期,公司仿制药一致性评价业务的收入分别为3205万、6281万和6271万,占当期主营业务收入的比例分别为23.78%、26.93%和18.08%。阳光诺和2021年一季度营收为9577.08万元,同比增长29.82%;实现归属于母公司股东的净利润2053.48万元,同比增长19.01%;实现扣除非经常性损益后归属于母公司股东的净利润2011.81万元,同比增长14.78%。阳光诺和2021年1-6月营业收入预计为2亿元到2.4亿元,较上年同期变动幅度为28.45%-54.14%;净利润预计为4500万元-5400万元,较上年同期变动幅度为12.03%-34.44%;归属于母公司股东的净利润预计为4350万元到5250万元,较上年同期变动幅度为6.49%-28.52%;阳光诺和2021年1-6月扣除非经常性损益后归属于母公司股东的净利润预计为4300万元到5300万元,较去年同期变动幅度为4.99%-29.41%。实控人利虔大专肄业IPO前,阳光诺和实际控制人利虔持股比例为36.78%,刘宇晶直接持有公司4,280,860股股份,持股7.13%,在公司担任董事、总经理职务。利虔,男,1981年11月出生,北京医科大学(现北京大学医学部)大专肄业。2002年7月至2005年6月,历任北京德众万全药物技术开发有限公司合成部实验员、项目经理、项目立项组组长;2005年6月至2014年6月,任北京聚德阳光医药科技有限公司执行董事、总经理;利虔2009年3月投资创建阳光诺和有限,2009年3月至2011年9月,任阳光诺和有限执行董事、总经理;2011年9月至2016年3月,任阳光诺和有限董事、总经理;2016年3月至2016年7月,任阳光诺和有限执行董事、总经理;2016年2月至今,任朗研生命执行董事;2016年3月至今,任百奥药业董事长;利虔2016年12月至今,任永安制药董事长;利虔现兼任朗研生命总经理,百奥药业总经理,北京屹东博杰科技有限责任公司监事;2020年3月至今,任阳光诺和董事长。此外,杭州方汭持股为4.75%,邵妍、托新权分别持股为4%,佛山景祥持股为3.38%,凯泰民德持股为3.07%;信德一期持股为2.68%,海达明德持股为2.61%,睿盈投资持股为2.33%,广州正达持股为2.23%;泰达盛林持股为2.2%;武汉火炬、武汉开投分别持股为1.82%,广发乾和持股为1.46%,民生投资持股为1.25%。IPO后,实际控制人利虔持股比例将进一步稀释为27.59%,刘宇晶持股为5.35%,杭州方汭持股为3.57%,邵妍、托新权分别持股为3%。———————————————雷递由资深媒体人雷建平创办,为头条签约作者,若转载请写明来源。","news_type":1,"symbols_score_info":{"688621":1}},"isVote":1,"tweetType":1,"viewCount":3003,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":120036245,"gmtCreate":1624287582087,"gmtModify":1624287582087,"author":{"id":"3546384736338140","authorId":"3546384736338140","name":"北_4560","avatar":"https://static.tigerbbs.com/711d3d2faa9de841ae9246d53fa589ec","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3546384736338140","authorIdStr":"3546384736338140"},"themes":[],"htmlText":"后续全让你吐出来","listText":"后续全让你吐出来","text":"后续全让你吐出来","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/120036245","repostId":"2145085011","repostType":2,"isVote":1,"tweetType":1,"viewCount":2643,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":130424242,"gmtCreate":1621562166086,"gmtModify":1621562166086,"author":{"id":"3546384736338140","authorId":"3546384736338140","name":"北_4560","avatar":"https://static.tigerbbs.com/711d3d2faa9de841ae9246d53fa589ec","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3546384736338140","authorIdStr":"3546384736338140"},"themes":[],"htmlText":"不是不跌,是不到时候[笑哭] ","listText":"不是不跌,是不到时候[笑哭] ","text":"不是不跌,是不到时候[笑哭]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/130424242","repostId":"2136604249","repostType":2,"isVote":1,"tweetType":1,"viewCount":2320,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":192443097,"gmtCreate":1621225411919,"gmtModify":1621225411919,"author":{"id":"3546384736338140","authorId":"3546384736338140","name":"北_4560","avatar":"https://static.tigerbbs.com/711d3d2faa9de841ae9246d53fa589ec","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3546384736338140","authorIdStr":"3546384736338140"},"themes":[],"htmlText":"都有问题,绝对的,被人家抓住把柄了。","listText":"都有问题,绝对的,被人家抓住把柄了。","text":"都有问题,绝对的,被人家抓住把柄了。","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/192443097","repostId":"1176859680","repostType":4,"isVote":1,"tweetType":1,"viewCount":2645,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":193529421,"gmtCreate":1620801206163,"gmtModify":1620801206163,"author":{"id":"3546384736338140","authorId":"3546384736338140","name":"北_4560","avatar":"https://static.tigerbbs.com/711d3d2faa9de841ae9246d53fa589ec","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3546384736338140","authorIdStr":"3546384736338140"},"themes":[],"htmlText":"继续","listText":"继续","text":"继续","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/193529421","repostId":"1125686038","repostType":4,"isVote":1,"tweetType":1,"viewCount":1824,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":312650419,"gmtCreate":1612144182931,"gmtModify":1703757893943,"author":{"id":"3546384736338140","authorId":"3546384736338140","name":"北_4560","avatar":"https://static.tigerbbs.com/711d3d2faa9de841ae9246d53fa589ec","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3546384736338140","authorIdStr":"3546384736338140"},"themes":[],"htmlText":"查吧[开心] ","listText":"查吧[开心] ","text":"查吧[开心]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/312650419","repostId":"2108224483","repostType":2,"isVote":1,"tweetType":1,"viewCount":2738,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":318464577,"gmtCreate":1611885027499,"gmtModify":1703755627943,"author":{"id":"3546384736338140","authorId":"3546384736338140","name":"北_4560","avatar":"https://static.tigerbbs.com/711d3d2faa9de841ae9246d53fa589ec","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3546384736338140","authorIdStr":"3546384736338140"},"themes":[],"htmlText":"支持,实事求是!再有钱能大过法?","listText":"支持,实事求是!再有钱能大过法?","text":"支持,实事求是!再有钱能大过法?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/318464577","repostId":"2106251849","repostType":2,"isVote":1,"tweetType":1,"viewCount":2700,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":332240458,"gmtCreate":1610419148574,"gmtModify":1703744170495,"author":{"id":"3546384736338140","authorId":"3546384736338140","name":"北_4560","avatar":"https://static.tigerbbs.com/711d3d2faa9de841ae9246d53fa589ec","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3546384736338140","authorIdStr":"3546384736338140"},"themes":[],"htmlText":"通过也拉不起股票,进入集采可以😊","listText":"通过也拉不起股票,进入集采可以😊","text":"通过也拉不起股票,进入集采可以😊","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/332240458","repostId":"2101625794","repostType":2,"repost":{"id":"2101625794","kind":"news","pubTimestamp":1609921407,"share":"https://www.laohu8.com/m/news/2101625794?lang=&edition=full","pubTime":"2021-01-06 16:23","market":"hk","language":"zh","title":"悦康药业(688658.SH):降血糖药盐酸二甲双胍片通过仿制药一致性评价","url":"https://stock-news.laohu8.com/highlight/detail?id=2101625794","media":"智通财经","summary":"智通财经APP讯,悦康药业(688658.SH)发布公告,近日,该公司收到国家药品监督管理局核准签发的关于盐酸二甲双胍片(0.25g)的《药品补充申请批准通知书》,该药品通过仿制药质量和疗效一致性评价。据悉,盐酸二甲双胍片为双胍类口服降血糖药物,适应人群广,成人和10岁及以上儿童和青少年均可适用。","content":"<html><body><p>智通财经APP讯,<a href=\"https://laohu8.com/S/688658\">悦康药业</a>(688658.SH)发布公告,近日,该公司收到国家药品监督管理局核准签发的关于盐酸二甲双胍片(0.25g)的《药品补充申请批准通知书》,该药品通过仿制药质量和疗效一致性评价。</p><p>据悉,盐酸二甲双胍片为双胍类口服降血糖药物,适应人群广,成人和10岁及以上儿童和青少年均可适用。</p></body></html>","source":"stock_zhitongcaijing","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>悦康药业(688658.SH):降血糖药盐酸二甲双胍片通过仿制药一致性评价</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n悦康药业(688658.SH):降血糖药盐酸二甲双胍片通过仿制药一致性评价\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-01-06 16:23 北京时间 <a href=http://www.zhitongcaijing.com/content/detail/389864.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP讯,悦康药业(688658.SH)发布公告,近日,该公司收到国家药品监督管理局核准签发的关于盐酸二甲双胍片(0.25g)的《药品补充申请批准通知书》,该药品通过仿制药质量和疗效一致性评价。据悉,盐酸二甲双胍片为双胍类口服降血糖药物,适应人群广,成人和10岁及以上儿童和青少年均可适用。</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/389864.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/bc7ad619aa7e42a7db4703997b65806b","relate_stocks":{"688658":"悦康药业"},"source_url":"http://www.zhitongcaijing.com/content/detail/389864.html","is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2101625794","content_text":"智通财经APP讯,悦康药业(688658.SH)发布公告,近日,该公司收到国家药品监督管理局核准签发的关于盐酸二甲双胍片(0.25g)的《药品补充申请批准通知书》,该药品通过仿制药质量和疗效一致性评价。据悉,盐酸二甲双胍片为双胍类口服降血糖药物,适应人群广,成人和10岁及以上儿童和青少年均可适用。","news_type":1,"symbols_score_info":{"688658":1}},"isVote":1,"tweetType":1,"viewCount":2953,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"defaultTab":"following","isTTM":false}